Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange 02:00:00 2024-06-13 EDT 5-day change 1st Jan Change
6,367 JPY -2.81% Intraday chart for Otsuka Holdings Co., Ltd. -1.49% +20.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026 CI
Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials MT
Japanese Shares Close Lower as JGB Yields Hit 12-Year High MT
Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial MT
Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy MT
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1 MT
Otsuka to stop development of Alzheimer's disease drug RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year Ending December 2024 CI
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT
Otsuka Holdings' Attributable Profit Jumps 26% in Q1 MT
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of 2024 CI
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024 CI
Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation MT
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024 CI
Otsuka Holdings Lowers 2023 Profit Outlook MT
Chart Otsuka Holdings Co., Ltd.
More charts
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
6,367 JPY
Average target price
6,473 JPY
Spread / Average Target
+1.66%
Consensus
  1. Stock Market
  2. Equities
  3. 4578 Stock
  4. News Otsuka Holdings Co., Ltd.
  5. Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial